GPP
PTLA

Great Point Partners’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Great Point Partners’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-50,000
Closed -$1.02M – 46
2016
Q1 		$1.02M Buy
+50,000
New +$1.59M 0.37% 29

Other funds holding PTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Great Point Partners's PTLA Position: Q2 2016 in Review

Great Point Partners sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2016, closing a stake of 50,000 shares — an estimated $1.02M sold.

Great Point Partners first reported a position in PTLA in Q1 2016 and held it in 1 quarter. The position peaked at $1.02M in Q1 2016. 159 funds tracked by Wall St. Rank hold PTLA as of Q2 2016.

  • Great Point Partners reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • Great Point Partners sold 50,000 Portola Pharmaceuticals, Inc. shares in Q2 2016, an estimated $1.02M.
  • Great Point Partners first reported a position in Portola Pharmaceuticals, Inc. in Q1 2016 and held it in 1 quarter.
  • Great Point Partners's Portola Pharmaceuticals, Inc. position peaked at $1.02M in Q1 2016.
  • 159 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2016.

Based on Great Point Partners's 13F filing for Q2 2016, filed 15 Aug 2016.